ABSTRACT
OBJECTIVE: To compare the molluscicidal effects and cost-effectiveness of 5% niclosamide ethanolamine salt granules (NEG) and 26% suspension concentrate of metalaldehyde and niclosamide ethanolamine salt (MNSC) . METHODS: Two plots with high Oncomelania hupensis snail density were selected as research areas in Nanjing Chemical Industry Zone, and 5% NEG (40 g/m2) and 26% MNSC (40 g/m2) were used by the spraying method for snail control in the two plots, and their molluscicidal effects and cost-effectiveness were investigated and statistically analyzed. RESULTS: There was no significant difference between 5% NEG and 26% MNSC in the molluscicidal effects. The cost of 5% NEG was 1.25 times higher than that of 26% MN-SC per ten thousand square meters in snail control. CONCLUSIONS: The cost of 5% NEG is higher than that of 26% MNSC per ten thousand square meters in snail control. Their molluscicidal effects are similar.
Subject(s)
Acetaldehyde/analogs & derivatives , Ethanolamines , Molluscacides , Snails , Acetaldehyde/economics , Acetaldehyde/pharmacology , Acetaldehyde/standards , Animals , Ethanolamine/economics , Ethanolamine/pharmacology , Ethanolamine/standards , Ethanolamines/economics , Ethanolamines/pharmacology , Ethanolamines/standards , Molluscacides/economics , Molluscacides/pharmacology , Molluscacides/standards , Niclosamide/economics , Niclosamide/pharmacology , Niclosamide/standards , Snails/drug effectsABSTRACT
An inhaled corticosteroid (ICS) and a long acting beta agonist (LABA) are combined in an inhaler for treatment of persistent asthma. There is evidence that maintenance therapy with a combination ICS/LABA inhaler improves clinical outcomes and reduces airflow obstruction in patients with persistent asthma, who are not well controlled even when using ICS maintenance therapy. There is evidence that a combination ICS/LABA inhaler may also play a role in initial maintenance therapy for patients with mild persistent asthma, who have never used ICS therapy. There is no evidence regarding the use of combination therapy in intermittent asthma. Oral candidal infections, hoarseness and pharyngolaryngeal pain are the most frequently reported adverse events. Combination inhaler therapy can improve compliance with guidelines that recommend a LABA only be used with concurrent ICS administration.
